Literature DB >> 12911531

Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.

Alicia J Jenkins1, Timothy J Lyons, Deyi Zheng, James D Otvos, Daniel T Lackland, Daniel McGee, W Timothy Garvey, Richard L Klein.   

Abstract

BACKGROUND: Lipoproteins may contribute to diabetic nephropathy. Nuclear magnetic resonance (NMR) can quantify subclasses and mean particle size of very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL), and LDL particle concentration. The relationship between detailed lipoprotein analyses and diabetic nephropathy is of interest.
METHODS: In a cross-sectional study, lipoproteins from 428 women and 540 men from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort were characterized by conventional lipid enzymology, NMR, apolipoprotein levels, and LDL oxidizibility. Linear regression was performed for each lipoprotein parameter versus log albumin excretion rate (AER), with and without covariates for age, diabetes duration, HbA1c, hypertension, body mass index, waist-hip ratio, and DCCT treatment group. Significance was taken at P < 0.05.
RESULTS: By multivariate analysis, conventional profile, total triglycerides, total- and LDL cholesterol, but not HDL cholesterol, were associated with AER. NMR-determined large, medium, and small VLDL were associated with AER in both genders (except large VLDL in women), and intermediate density lipoprotein (IDL) was associated with AER (men only). LDL particle concentration and ApoB were positively associated with AER (in men and in the total cohort), and there was a borderline inverse association between LDL diameter and AER in men. Small HDL was positively associated with AER and a borderline negative association was found for large HDL. No associations were found with ApoA1, Lp(a), or LDL oxidizibility.
CONCLUSION: Potentially atherogenic lipoprotein profiles are associated with renal dysfunction in type 1 diabetes and further details are gained from NMR analysis. Longitudinal studies are needed to determine if dyslipoproteinemia can predict patients at risk of nephropathy, or if lipoprotein-related interventions retard nephropathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911531     DOI: 10.1046/j.1523-1755.2003.00164.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  56 in total

1.  Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Authors:  Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Nephrol Dial Transplant       Date:  2012-01-28       Impact factor: 5.992

2.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

3.  Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes.

Authors:  J L Barth; Y Yu; W Song; K Lu; A Dashti; Y Huang; W S Argraves; T J Lyons
Journal:  Diabetologia       Date:  2007-08-04       Impact factor: 10.122

Review 4.  The pathologic continuum of diabetic vascular disease.

Authors:  Gabriela Orasanu; Jorge Plutzky
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

5.  Liver X receptors preserve renal glomerular integrity under normoglycaemia and in diabetes in mice.

Authors:  Monika Patel; Xiaoxin X Wang; Lilia Magomedova; Rohan John; Adil Rasheed; Hannah Santamaria; Weidong Wang; Ricky Tsai; Liru Qiu; Arturo Orellana; Andrew Advani; Moshe Levi; Carolyn L Cummins
Journal:  Diabetologia       Date:  2013-11-08       Impact factor: 10.122

6.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

Review 7.  Hypertension management in patients with diabetic nephropathy.

Authors:  Anthony L McCall
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

8.  Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.

Authors:  Ying Zhang; Alicia J Jenkins; Arpita Basu; Julie A Stoner; Maria F Lopes-Virella; Richard L Klein; Timothy J Lyons
Journal:  J Lipid Res       Date:  2015-12-09       Impact factor: 5.922

9.  Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy.

Authors:  Anne Julie Overgaard; Henning Gram Hansen; Maria Lajer; Lykke Pedersen; Lise Tarnow; Peter Rossing; James N McGuire; Flemming Pociot
Journal:  Proteome Sci       Date:  2010-02-03       Impact factor: 2.480

10.  Diabetic nephropathy.

Authors:  Themis Zelmanovitz; Fernando Gerchman; Amely Ps Balthazar; Fúlvio Cs Thomazelli; Jorge D Matos; Luís H Canani
Journal:  Diabetol Metab Syndr       Date:  2009-09-21       Impact factor: 3.320

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.